| Entry |
|
|---|
| Name |
Ketoconazole (JP17/USP);
Nizoral (TN);
Xolegel (TN)
|
|---|
| Product |
|
|---|
| Generic |
KETACONAZOLE (Mylan Pharmaceuticals), KETOCONAZOLE (A-S Medication Solutions), KETOCONAZOLE (A-S Medication Solutions), KETOCONAZOLE (Bryant Ranch Prepack), KETOCONAZOLE (E. Fougera & Co. a division of Fougera Pharmaceuticals), KETOCONAZOLE (Golden State Medical Supply), KETOCONAZOLE (Golden State Medical Supply), KETOCONAZOLE (IPG PHARMACEUTICALS), KETODAN (Medimetriks Pharmaceuticals), KETOCONAZOLE (Mylan Pharmaceuticals), KETOCONAZOLE (NORTHSTAR RX LLC), KETOCONAZOLE (NuCare Pharmaceuticals), KETOCONAZOLE (NuCare Pharmaceuticals), KETOCONAZOLE (NuCare Pharmaceuticals), KETOCONAZOLE (PD-Rx Pharmaceuticals), KETOCONAZOLE (PD-Rx Pharmaceuticals), KETOCONAZOLE (Patriot Pharmaceuticals), KETOCONAZOLE (Perrigo New York), KETOCONAZOLE (Perrigo New York), KETOCONAZOLE (Preferred Pharmaceuticals), KETOCONAZOLE (Preferred Pharmaceuticals), KETOCONAZOLE (Preferred Pharmaceuticals), KETOCONAZOLE (Proficient Rx LP), KETOCONAZOLE (Proficient Rx LP), KETOCONAZOLE (REMEDYREPACK), KETOCONAZOLE (REMEDYREPACK), KETOCONAZOLE (REMEDYREPACK), KETOCONAZOLE (REMEDYREPACK), KETOCONAZOLE (REMEDYREPACK), KETOCONAZOLE (Strides Shasun Limited), KETOCONAZOLE (THIRTY MADISON), KETOCONAZOLE (TOLMAR), KETOCONAZOLE (Taro Pharmaceuticals U.S.A.), KETOCONAZOLE (Taro Pharmaceuticals U.S.A.), KETOCONAZOLE (Teva Pharmaceuticals USA) |
|---|
| Formula |
C26H28Cl2N4O4
|
|---|
| Exact mass |
530.1488
|
|---|
| Mol weight |
531.4309
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antifungal
DG01883 Imidazole antifungal
Metabolizing enzyme inhibitor
DG01641 CYP2C8 inhibitor
DG01933 CYP2C19 inhibitor
DG02852 CYP3A inhibitor
Transporter inhibitor
DG01622 ABCB1 (P-GP) inhibitor
|
|---|
| Remark |
| Therapeutic category: | 2655 |
|
|---|
| Efficacy |
Antifungal, Ergosterol biosynthesis inhibitor |
|---|
| Disease |
Seborrheic dermatitis [DS: H01652] Tinea (pityriasis) versicolor [DS: H01334] |
|---|
| Comment |
Imidazole derivative
Racemic mixture of two cis-enantiomers [The diagram shows the (2S,4R)-isomer.]
|
|---|
| Target |
sterol 14alpha-demethylase [KO: K05917] |
|---|
| Pathway |
|
|---|
| Interaction |
CYP inhibition: CYP3A [HSA: 1576 1577 1551], CYP2C8 [HSA: 1558], CYP2C19 [HSA: 1557]
Transporter inhibition: ABCB1 [HSA: 5243]
 |
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE
D01A ANTIFUNGALS FOR TOPICAL USE
D01AC Imidazole and triazole derivatives
D01AC08 Ketoconazole
D00351 Ketoconazole (JP17/USP) <JP/US>
G GENITO URINARY SYSTEM AND SEX HORMONES
G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01AF Imidazole derivatives
G01AF11 Ketoconazole
D00351 Ketoconazole (JP17/USP) <JP/US>
J ANTIINFECTIVES FOR SYSTEMIC USE
J02 ANTIMYCOTICS FOR SYSTEMIC USE
J02A ANTIMYCOTICS FOR SYSTEMIC USE
J02AB Imidazole derivatives
J02AB02 Ketoconazole
D00351 Ketoconazole (JP17/USP) <JP/US>
USP drug classification [BR:br08302]
Antifungals
Ketoconazole
D00351 Ketoconazole (JP17/USP)
Dermatological Agents
Topical Anti-infectives
Antifungals, dermatological
Ketoconazole
D00351 Ketoconazole (JP17/USP)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
26 Epidermides
265 Antiparasitic dermatosis agents
2655 Imidazoles
D00351 Ketoconazole (JP17/USP)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00351 Ketoconazole
D00351 Ketoconazole solution
D00351 Ketoconazole lotion
D00351 Ketoconazole cream
Antiinfectives [br08350.html]
Antifungals
D00351
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00351
Rx-to-OTC switch list in the USA [br08315.html]
D00351
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 36
1 C1z C 16.6092 -16.9097
2 C8y C 15.4102 -16.2195
3 O2x O 17.0363 -18.2256
4 C1b C 15.5740 -17.8163
5 O2x O 17.7323 -16.0907
6 C8y C 15.4102 -14.8332
7 C8x C 14.2111 -16.9097
8 C1y C 18.4225 -18.2256
9 N4y N 14.1235 -17.8220
10 C1x C 18.8611 -16.9097
11 C8x C 14.2111 -14.1430
12 X Cl 16.6092 -14.1430
13 C8x C 13.0121 -16.2195
14 C1b C 19.8437 -18.9977
15 C8x C 12.9946 -17.0033
16 C8x C 13.6906 -19.1381
17 C8y C 13.0121 -14.8332
18 O2a O 21.2066 -18.0677
19 C8x C 11.8716 -17.8220
20 N5x N 12.3044 -19.1381
21 X Cl 11.8132 -14.1430
22 C8y C 22.5987 -18.0736
23 C8x C 23.2889 -19.2784
24 C8x C 23.3006 -16.8745
25 C8x C 24.6750 -19.2843
26 C8x C 24.6809 -16.8803
27 C8y C 25.3711 -18.0794
28 N1y N 26.7513 -18.0853
29 C1x C 27.4415 -19.2901
30 C1x C 27.4475 -16.8920
31 C1x C 28.8278 -19.2960
32 C1x C 28.8336 -16.8920
33 N1y N 29.5238 -18.0911
34 C5a C 30.9101 -18.0270
35 C1a C 31.5943 -19.3018
36 O5a O 31.6060 -16.9037
BOND 40
1 1 2 1 #Down
2 1 3 1
3 1 4 1 #Up
4 1 5 1
5 2 6 1
6 2 7 2
7 3 8 1
8 4 9 1
9 5 10 1
10 6 11 2
11 6 12 1
12 7 13 1
13 8 14 1 #Up
14 9 15 1
15 9 16 1
16 11 17 1
17 14 18 1
18 15 19 2
19 16 20 2
20 17 21 1
21 18 22 1
22 22 23 2
23 22 24 1
24 23 25 1
25 24 26 2
26 25 27 2
27 27 28 1
28 28 29 1
29 28 30 1
30 29 31 1
31 30 32 1
32 31 33 1
33 33 34 1
34 34 35 1
35 34 36 2
36 8 10 1
37 13 17 2
38 19 20 1
39 26 27 1
40 32 33 1
|
|---|
|
